493 related articles for article (PubMed ID: 25673642)
1. Atg7 Overcomes Senescence and Promotes Growth of BrafV600E-Driven Melanoma.
Xie X; Koh JY; Price S; White E; Mehnert JM
Cancer Discov; 2015 Apr; 5(4):410-23. PubMed ID: 25673642
[TBL] [Abstract][Full Text] [Related]
2. Autophagy sustains mitochondrial glutamine metabolism and growth of BrafV600E-driven lung tumors.
Strohecker AM; Guo JY; Karsli-Uzunbas G; Price SM; Chen GJ; Mathew R; McMahon M; White E
Cancer Discov; 2013 Nov; 3(11):1272-85. PubMed ID: 23965987
[TBL] [Abstract][Full Text] [Related]
3. Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.
Vredeveld LC; Possik PA; Smit MA; Meissl K; Michaloglou C; Horlings HM; Ajouaou A; Kortman PC; Dankort D; McMahon M; Mooi WJ; Peeper DS
Genes Dev; 2012 May; 26(10):1055-69. PubMed ID: 22549727
[TBL] [Abstract][Full Text] [Related]
4. Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma.
Marsh Durban V; Deuker MM; Bosenberg MW; Phillips W; McMahon M
J Clin Invest; 2013 Dec; 123(12):5104-18. PubMed ID: 24200692
[TBL] [Abstract][Full Text] [Related]
5. Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells.
Li Z; Jiang K; Zhu X; Lin G; Song F; Zhao Y; Piao Y; Liu J; Cheng W; Bi X; Gong P; Song Z; Meng S
Cancer Lett; 2016 Jan; 370(2):332-44. PubMed ID: 26586345
[TBL] [Abstract][Full Text] [Related]
6. Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor.
Bonnevaux H; Lemaitre O; Vincent L; Levit MN; Windenberger F; Halley F; Delorme C; Lengauer C; Garcia-Echeverria C; Virone-Oddos A
Mol Cancer Ther; 2016 Jul; 15(7):1460-71. PubMed ID: 27196754
[TBL] [Abstract][Full Text] [Related]
7. Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells.
Fedorenko IV; Abel EV; Koomen JM; Fang B; Wood ER; Chen YA; Fisher KJ; Iyengar S; Dahlman KB; Wargo JA; Flaherty KT; Sosman JA; Sondak VK; Messina JL; Gibney GT; Smalley KS
Oncogene; 2016 Mar; 35(10):1225-35. PubMed ID: 26073081
[TBL] [Abstract][Full Text] [Related]
8. Autophagy promotes BrafV600E-driven lung tumorigenesis by preserving mitochondrial metabolism.
Strohecker AM; White E
Autophagy; 2014 Feb; 10(2):384-5. PubMed ID: 24362353
[TBL] [Abstract][Full Text] [Related]
9. Atg7 cooperates with Pten loss to drive prostate cancer tumor growth.
Santanam U; Banach-Petrosky W; Abate-Shen C; Shen MM; White E; DiPaola RS
Genes Dev; 2016 Feb; 30(4):399-407. PubMed ID: 26883359
[TBL] [Abstract][Full Text] [Related]
10. Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice.
Goel VK; Ibrahim N; Jiang G; Singhal M; Fee S; Flotte T; Westmoreland S; Haluska FS; Hinds PW; Haluska FG
Oncogene; 2009 Jun; 28(23):2289-98. PubMed ID: 19398955
[TBL] [Abstract][Full Text] [Related]
11. Deciphering the Role of Oncogenic MITFE318K in Senescence Delay and Melanoma Progression.
Bonet C; Luciani F; Ottavi JF; Leclerc J; Jouenne FM; Boncompagni M; Bille K; Hofman V; Bossis G; Marco de Donatis G; Strub T; Cheli Y; Ohanna M; Luciano F; Marchetti S; Rocchi S; Birling MC; Avril MF; Poulalhon N; Luc T; Hofman P; Lacour JP; Davidson I; Bressac-de Paillerets B; Ballotti R; Marine JC; Bertolotto C
J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376192
[TBL] [Abstract][Full Text] [Related]
12. An autophagy-driven pathway of ATP secretion supports the aggressive phenotype of BRAF
Martin S; Dudek-Peric AM; Garg AD; Roose H; Demirsoy S; Van Eygen S; Mertens F; Vangheluwe P; Vankelecom H; Agostinis P
Autophagy; 2017 Sep; 13(9):1512-1527. PubMed ID: 28722539
[TBL] [Abstract][Full Text] [Related]
13. Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma.
Yang H; Kircher DA; Kim KH; Grossmann AH; VanBrocklin MW; Holmen SL; Robinson JP
Oncogene; 2017 Jul; 36(27):3842-3851. PubMed ID: 28263969
[TBL] [Abstract][Full Text] [Related]
14. Gossypin as a novel selective dual inhibitor of V-RAF murine sarcoma viral oncogene homolog B1 and cyclin-dependent kinase 4 for melanoma.
Bhaskaran S; Dileep KV; Deepa SS; Sadasivan C; Klausner M; Krishnegowda NK; Tekmal RR; VandeBerg JL; Nair HB
Mol Cancer Ther; 2013 Apr; 12(4):361-72. PubMed ID: 23543365
[TBL] [Abstract][Full Text] [Related]
15. Metastatic risk and resistance to BRAF inhibitors in melanoma defined by selective allelic loss of ATG5.
García-Fernández M; Karras P; Checinska A; Cañón E; Calvo GT; Gómez-López G; Cifdaloz M; Colmenar A; Espinosa-Hevia L; Olmeda D; Soengas MS
Autophagy; 2016 Oct; 12(10):1776-1790. PubMed ID: 27464255
[TBL] [Abstract][Full Text] [Related]
16. Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy.
Eng CH; Wang Z; Tkach D; Toral-Barza L; Ugwonali S; Liu S; Fitzgerald SL; George E; Frias E; Cochran N; De Jesus R; McAllister G; Hoffman GR; Bray K; Lemon L; Lucas J; Fantin VR; Abraham RT; Murphy LO; Nyfeler B
Proc Natl Acad Sci U S A; 2016 Jan; 113(1):182-7. PubMed ID: 26677873
[TBL] [Abstract][Full Text] [Related]
17. Sox2 is not required for melanomagenesis, melanoma growth and melanoma metastasis in vivo.
Cesarini V; Guida E; Todaro F; Di Agostino S; Tassinari V; Nicolis S; Favaro R; Caporali S; Lacal PM; Botti E; Costanzo A; Rossi P; Jannini EA; Dolci S
Oncogene; 2017 Aug; 36(31):4508-4515. PubMed ID: 28368402
[TBL] [Abstract][Full Text] [Related]
18. Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model.
Grossauer S; Koeck K; Murphy NE; Meyers ID; Daynac M; Truffaux N; Truong AY; Nicolaides TP; McMahon M; Berger MS; Phillips JJ; James CD; Petritsch CK
Oncotarget; 2016 Nov; 7(46):75839-75853. PubMed ID: 27713119
[TBL] [Abstract][Full Text] [Related]
19. Loss of Ambra1 promotes melanoma growth and invasion.
Di Leo L; Bodemeyer V; Bosisio FM; Claps G; Carretta M; Rizza S; Faienza F; Frias A; Khan S; Bordi M; Pacheco MP; Di Martino J; Bravo-Cordero JJ; Daniel CJ; Sears RC; Donia M; Madsen DH; Guldberg P; Filomeni G; Sauter T; Robert C; De Zio D; Cecconi F
Nat Commun; 2021 May; 12(1):2550. PubMed ID: 33953176
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
